*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

Plateau Treasures Limited

高原之寶有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8402)

VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION MEMORANDUM

The board (the "**Board**") of directors (the "**Director(s)**") of Plateau Treasures Limited (the "**Company**") is pleased to announce that on 28 May 2026, the Company entered into a strategic cooperation memorandum (the "**Memorandum**") with Dr. Ya Cai ("**Dr. Cai**").

Pursuant to the Memorandum, the Company and Dr. Cai intend to jointly leverage their respective resources and research and development advantages to carry out research and development of great-health-related products, market expansion and promotion in the great health industry, etc., and to promote the implementation of in-depth cooperation and concrete execution of their collaboration through business planning exchanges, discussion of cooperation models, and other means. The core elements of the cooperation include:

a) Introduction of technical talents: The parties intend to cooperate in depth, with Dr. Cai guiding the technological layout and research and development system establishment in the great health industry.

b) Synergistic empowerment of technology research and development: Dr. Cai will provide the Company with core technical support in plant active ingredients, plant flavonoids, food and drug homologous formulas, etc., and assist the Company in establishing a comprehensive health research and development and industrialisation system. Dr. Cai warrants that all technologies, patents and formulas provided are clear in ownership, free of defects in title, free of encumbrances, free of exclusive third-party licences, and free of infringement disputes, and will grant the Company exclusive priority cooperation rights in the selected cooperation sectors.

c) Industrial base layout: Leveraging its advantages in the Hong Kong and Southeast Asian markets, the Company will establish a wholly-owned subsidiary in Chinese Mainland at an appropriate time to serve as the Group's great health industry research and development, production and operation base, supporting project implementation and business expansion.

The Memorandum is valid for 12 months. During the cooperation period: (i) Dr. Cai's core technology and research and development team will prioritise empowering the Company to ensure the Company's technological barriers and product iteration capabilities; and (ii) Dr. Cai and his affiliated parties and core team may not, directly or indirectly, negotiate or cooperate with any third party in competitive businesses of the same type, including plant technology, food and drug homologous health beverages, and functional foods.

Except for certain provisions concerning confidentiality, exclusivity, intellectual property undertakings and costs and expenses, the Memorandum is not legally binding on the Company or Dr. Cai.

REASONS FOR AND BENEFITS OF ENTERING INTO THE MEMORANDUM

The Board considers that the execution of the Memorandum will enable the Company to leverage Dr. Cai's authoritative position in academia and industry, as well as his abundant resources and experience in plant extraction and functional food research and development, so as to (i) expand the Company's business portfolio; (ii) enhance our competitive strength in the health and silver economy industries; and (iii) maximise the business value of the Company and the interests of the Company's shareholders. Therefore, the execution of the Memorandum is in the overall interests of the Company and its shareholders.

INFORMATION ON DR. YA CAI

Dr. Cai holds a PhD in Plant Polyphenol Chemistry from the University of Sheffield, UK, and is a global leader in plant science and technology. Dr. Cai has 40 years of global experience in plant extraction and functional food research and development. He previously served as Global Principal Plant Expert at Unilever and founder of Unilever China Research Institute. He is a pre-eminent scholar in the international flavonoid/polyphenol field. In Mainland China, Dr. Cai controls several enterprises, including Shanghai Jian Shi Xing Biotechnology Co., Ltd.（上海健士星生物科技有限公司）, which are "chip-level research and development enterprises" in the plant health sector, focusing on the in-depth development of food and drug homologous ingredients and vine tea (dihydromyricetin, DHM), creating a portfolio of functional foods and healthy beverages.

The Board hereby emphasises that the strategic cooperation under the Memorandum may or may not materialise, and the strategic cooperation memorandum is not intended to be legally binding. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Plateau Treasures Limited
Wei Guangjun
Chairman and Executive Director

Hong Kong, 28 May 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Wei Guangjun (Chairman), Mr. Huang Fu Tang, Ms. Chen Xiaoyu and Mr. Ong Cheng Yew; one nonexecutive Director, namely, Ms. Lin Xiaoqin; and three independent non-executive Directors, namely, Mr. Wong Carson Ka Chun, Ms. Chen Li and Mr. Ji Gaofeng.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement, and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statements in this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the Stock Exchange's website at www.hkexnews.hk for at least 7 days from the date of its publication. This announcement will also be published on the Company's website at www.8402.com.hk.